NCT07109284View on ClinicalTrials.gov

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

December 31, 2030

Conditions
ER+HER2- Breast Cancer
Interventions
BIOLOGICAL

Sacituzumab tirumotecan

Sacituzumab tirumotecan 5 mg/kg, intravenously (iv), Q2W

BIOLOGICAL

Tagitanlimab

Tagitanlimab 900mg, intravenously (iv), Q2W

All Listed Sponsors
lead

West China Hospital

OTHER